Colorectal cancer: Response to sunitinib in a heavily pretreated colorectal cancer patient

Anti-Cancer Drugs

Volumn 21, Issue SUPPL.1, 2010, Pages

  Gasent Blesa, Joan Manel ^a   Pulido, Enrique Grande ^b  

^a HOSPITAL MARINA ALTA   (Spain)

^b PFIZER INC   (United States)

Author keywords

Colon cancer; Heavily pretreated patient; Sunitinib

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; RALTITREXED; SUNITINIB; TEGAFUR; ZOLEDRONIC ACID;

ADULT; ARTICLE; BLEEDING; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PAIN; CANCER RADIOTHERAPY; CANCER RECURRENCE; CASE REPORT; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; FUNCTIONAL DISEASE; HEMICOLECTOMY; HUMAN; MALE; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; PELVIS PAIN SYNDROME; PRIORITY JOURNAL; RECTUM FISTULA; TREATMENT DURATION; TREATMENT RESPONSE;

ACTIVITIES OF DAILY LIVING; ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; CARCINOEMBRYONIC ANTIGEN; COLORECTAL NEOPLASMS; COMPASSIONATE USE TRIALS; HUMANS; INDOLES; MALE; MIDDLE AGED; PAIN; PYRROLES;

EID: 76449119868     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cad.0000361533.36428.0b     Document Type: Article

References (15)

1. Saltz LB, Rosen LS, Marshall JL, Belt RJ, Hurwitz HI, Eckhardt GS, et al. Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. J Clin Oncol 2007; 25:4793-4799.
2. Jemal A, Siegel R,Ward E, Murray T, Xu J, Thun MJ. Cancer Statistics, 2007. CA Cancer J Clin 2007; 57:43-66.
3. Reinacher-Schick A, Pohl M, Schmiegel W. Drug insight: antiangiogenic therapies for gastrointestinal cancers. Focus on monoclonal antibodies. Gastroenterol Hepatol 2008; 5:250-267.
4. Cilley JC, Barfi K, Benson AB III, Mulcahy MF. Bevacizumab in the treatment of colorectal cancer. Expert Opin Biol Ther 2007; 7:739-749.
5. Obrand DI, Gordon PH. Incidence and patterns of recurrence following curative resection for colorectal carcinoma. Dis Colon Rectum 1997; 40:1-24.
6. Van Cutsen E, Oliveira J. Colon cancer: ESMO clinical recommendations for diagnosis, adjuvant treatment and follow-up. Ann Oncol 2008; 19 (Suppl 2):ii29-ii30.
7. Ishigami SI, Arii S, Furutami M. Predictive value of vascular endothelial growth factor (VEGF) in metastasis and prognosis of human colorectal cancer. Br J Cancer 1998; 78:1379-1384.
8. Kramer I, Lipp HP. Bevacizumab, a humanized anti-angiogenic monoclonal antibody for the treatment of colorectal cancer. J Clin Pharm Ther 2007; 32:1-14.
9. Pohl A, Zhang W, Ning Y, Manegold PC, Lurje G, Lenz HJ. Targeting metastatic colorectal cancer in 2008: a long way from 5-FU. Oncology (Williston Park) 2008; ;22:456-462.
10. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ. Cancer statistics 2006. CA Cancer J Clin 2006; 56:106-130.
11. Christensen JG. A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumour activities. Ann Oncol 2007; 18 (Suppl 10):3-10.
12. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003; 9:327-337.
13. Marzola P, Degrassi A, Calderan L, Farace P, Nicolato E, Crescimanno C, et al. Early antiangiogenic activity of SU11248 evaluated in vivo by dynamic contrast-enhanced magnetic resonance imaging in an experimental model of colon carcinoma. Clin Cancer res 2005; 11:5827-5832.
14. Fakih MG. CEA Monitoring in colorectal cancer. Oncology 2006; 20:579-592.
15. Duffy MJ, Van Dalen A, Haglund G, Hansson L, Holinski-Feder E, Klapdor R, et al. Tumor markers in colorectal cancer: European Group on Tumor Markers (EGTM) guidelines for clinical use. Eur J Cancer 2007; 43:1348-1360